MedTrace Logo

Study on GS300 on NAFLD

NCT04887766 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2022-01-24

No results posted yet for this study

Summary

To determine the efficacy of GS300 when administered for 24 weeks in patients with Nonalcoholic Fatty Liver Disease (NAFLD).

Conditions

Interventions

DEVICE

GS300

Gelesis300 hydrogel in gelatin capsules

DEVICE

Placebo

Placebo capsules

Sponsors & Collaborators

  • Gelesis, Inc.

    lead INDUSTRY

Principal Investigators

  • Hassan M Heshmati, MD · Gelesis, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
22 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2023-12-31
Completion
2023-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04887766 on ClinicalTrials.gov